SEC Probing King Pricing and Rebates
- Share via
From Reuters
King Pharmaceuticals Inc. said securities regulators are investigating its pricing and rebate practices and have subpoenaed various documents.
The drug maker said it received a letter and a subpoena from the Securities and Exchange Commission. King’s auditors, PricewaterhouseCoopers, also received a subpoena about the company.
Shares of Bristol, Tenn.-based King fell $3.73 to close at $12.17 on the New York Stock Exchange.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
